BOPI 04 BR/2023 REPERTOIRE NUMERIQUE 13 (11) 20884 (51) A61P 11/00 (2018.01); C07D 239/69 (2018.01); C07D 515/08 (2018.01) (21) 1202100456 - PCT/US2020/026331 (22) 02/04/2020 (30) US n° 62/828, 699 du 03/04/2019 (54) Cystic fibrosis transmembrane conductance regulator modulating agents. (72) ARUMUGAM, Vijayalaksmi (US); CLEVELAND, Thomas (US); FRIEMAN, Bryan A. (US); ABELA, Alexander Russell (US); ANDERSON, Corey Don (US); ABRAHAM, Sunny (US); CHAU, Jaclyn (US); CLEMENS, Jeremy (US) et DWIGHT, Timothy A. (US) (73) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, BOSTON, Massachusetts 02210 (US) (74) SPOOR & FISHER Inc. NGWAFOR & PARTNERS Sarl, The House of Gideon, Golf/Bastos Quarters, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed. Compound (I) Consulter le mémoire ________________________________________ (11) 20885 (51) A61K 31/496 (2018.01); A61K 31/5377 (2018.01); A61K 45/06 (2018.01); A61P 25/00 (2018.01) (21) 1202100469 - PCT/IB2020/053382 (22) 09/04/2020 (30) HU n° P1900121 du 10/04/2019 (54) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder. (72) ROMÁN Viktor (HU); ADHAM-PARANGI, Nika (HU); ROGER Earley, Willie (HU) et PO-JEN YEUNG, Paul (HU) (73) Richter Gedeon Nyrt., Gyömröi ύt 19-21., H1103 BUDAPEST (HU) (74) SPOOR & FISHER Inc. NGWAFOR & PARTNERS Sarl, The House of Gideon, Golf/Bastos Quarters, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) The present invention relates to trans-N-[4-[2-[4- (2,3-dichlorophenyl) piperazin-1yl|ethyl]cyclohexyl]-N'N'-dimethylurea (cariprazine), its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations for use in the treatment of symptoms of autism spectrum disorder in general, and preferably the object of the present invention is to treat one or more symptoms of autism. Furthermore, it was also found that cariprazine. its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations are suitable for treatment of conditions such as Asperger's syndrome, atypical autism (otherwise known as pervasive developmental disorder not otherwise specified; PDD-NOS), Rett syndrome, childhood disintegrative disorder, attention deficit hyperactivity disorder (ADHD) and sensory integration dysfunction.
RkJQdWJsaXNoZXIy MTM1NDc3MA==